Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
| Indexado |
|
||||
| DOI | 10.1016/J.JACI.2018.09.033 | ||||
| Año | 2019 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Abstract
Conclusion: These data support the long-term safety and efficacy of mepolizumab in patients with SEA.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Khatri, Sumita | Mujer |
Cleveland Clin Fdn - Estados Unidos
Cleveland Clinic Foundation - Estados Unidos |
| 2 | Moore, Wendy | Mujer |
Wake Forest Sch Med - Estados Unidos
Wake Forest School of Medicine - Estados Unidos Wake Forest University School of Medicine - Estados Unidos |
| 3 | Gibson, Peter G. | Hombre |
UNIV NEWCASTLE - Australia
University of Newcastle, Australia - Australia The University of Newcastle, Australia - Australia |
| 4 | Leigh, Richard | Hombre |
Univ Calgary - Canadá
University of Calgary - Canadá Cumming School of Medicine - Canadá |
| 5 | Bourdin, Arnaud | Hombre |
Univ Montpellier - Francia
CHU Montpellier - Francia Physiologie et Médecine Expérimentale du Cœur et des Muscles - Francia Hopital Arnaud de Villeneuve - Francia |
| 6 | Maspero, Jorge | Hombre |
Fdn Cidea Allergy & Resp Res Unit - Argentina
Fundación Cidea Allergy and Respiratory Research Unit - Argentina |
| 7 | Barros, M. | Hombre |
Universidad de Valparaíso - Chile
Hospital Carlos Van Buren - Chile Hosp Carlos Van Buren - Chile |
| 8 | Buhl, R. | Hombre |
Mainz Univ Hosp - Alemania
Klinikum der Johannes-Gutenberg-Universität und Fachbereich Medizin - Alemania Universitätsmedizin Mainz - Alemania |
| 9 | Howarth, Peter | Hombre |
Univ Southampton - Reino Unido
Southampton Gen Hosp - Reino Unido GSK House - Reino Unido University of Southampton, Faculty of Medicine - Reino Unido GlaxoSmithKline plc. - Reino Unido |
| 10 | Albers, Frank C. | Hombre |
GSK - Estados Unidos
GlaxoSmithKline, USA - Estados Unidos GlaxoSmithKline plc. - Estados Unidos |
| 11 | Bradford, Eric S. | Hombre |
GSK - Estados Unidos
GlaxoSmithKline, USA - Estados Unidos GlaxoSmithKline plc. - Estados Unidos |
| 12 | Gilson, Martyn | Hombre |
GSK - Reino Unido
GlaxoSmithKline plc. - Reino Unido |
| 13 | Price, Robert G. | Hombre |
GSK - Reino Unido
GlaxoSmithKline plc. - Reino Unido |
| 14 | Yancey, Steven W. | Hombre |
GSK - Estados Unidos
GlaxoSmithKline, USA - Estados Unidos GlaxoSmithKline plc. - Estados Unidos |
| 15 | Ortega, Hector | Hombre |
GSK - Estados Unidos
GlaxoSmithKline, USA - Estados Unidos GlaxoSmithKline plc. - Estados Unidos |
| Fuente |
|---|
| National Institutes of Health |
| Novartis |
| National Heart, Lung, and Blood Institute |
| GlaxoSmithKline |
| National Health and Medical Research Council |
| Sanofi |
| Regeneron Pharmaceuticals |
| AstraZeneca |
| Meso Scale Diagnostics |
| Boehringer Ingelheim |
| MedImmune |
| GlaxoSmithKline (GSK) |
| North Carolina GlaxoSmithKline Foundation |
| Sanofi Aventis |
| Roche |
| Chiesi Farmaceutici |
| Teva Pharmaceutical Industries |
| Sanofi Regeneron |
| Pearl Therapeutics |
| Agradecimiento |
|---|
| This study was funded by GlaxoSmithKline (GSK ID: MEA115666; ClinicalTrials.gov number: NCT01691859). |
| Disclosure of potential conflict of interest: S. Khatri reports being an investigator in clinical trials in relation to GlaxoSmithKline and Boston Scientific, for which her institution is compensated for time related to the study. W. Moore reports receiving research grants from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, Pearl Therapeutics, Sanofi Regeneron, and the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI), and has been an advisory board consultant for AstraZeneca and Sanofi Regeneron. P. G. Gibson reports receiving personal fees from AstraZeneca, GlaxoSmithKline, and Novartis and a research grant from GlaxoSmithKline and the National Health and Medical Research Council (NHMRC). R. Leigh reports receiving honoraria and speakers’ fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and TEVA; his institution has also received research funding from AstraZeneca, GlaxoSmithKline, MedImmune, Novartis, and Sanofi for clinical trials in which he was a site investigator. A. Bourdin reports receiving personal fees, research grants, and nonfinancial support from GlaxoSmithKline; personal fees and nonfinancial support from AstraZeneca and Novartis; research grants from MSD; research grants and personal fees from Actelion; and personal fees and nonfinancial support from Chiesi. J. Maspero reports attending focus groups and boards for AstraZeneca and receiving personal fees from Novartis, AstraZeneca, GlaxoSmithKline, Sanofi, and Uriach. M. Barros reports receiving honoraria from Boehringer Ingelheim and Grifols for lectures and Advisory boards and has been involved as Principal Investigator in clinical trials for GlaxoSmithKline, Pearl Therapeutics, Sanofi Aventis, and Chiesi. R. Buhl reports personal fees from AstraZeneca, Chiesi, Teva, and Cipla; grants and personal fees from Boehringer Ingelheim, Novartis, and Roche; and grants from GlaxoSmithKline, all of which are outside the submitted work. P. Howarth, F. C. Albers, E. S. Bradford, M. Gilson, R. G. Price, and S. W. Yancy are all employees of GlaxoSmithKline and hold stocks/shares in GlaxoSmithKline. H. Ortega is a former employee of GlaxoSmithKline and holds stocks/shares in GlaxoSmithKline. |
